68-29-05

TO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

MOF.		Application Number	10/698,983
TRANSMITTA	L	Filing Date	10/31/2003
FORM		First Named Inventor	Howard Sands
(to be used for all correspondence after i	nitial filing)	Art Unit	1614
		Examiner Name	Not yet assigned
Total Number of Pages in This Submission	9	Attorney Docket Number	12636-304.201
	ENCLOSUI	RES (Check all that apply)	
Fee Transmittal Form	Drawing	g(s)	After Allowance communication to Technology Center (TC)
Fee Attached	Licensir	g-related Papers	Appeal Communication to Board of Appeals and Interferences
Amendment/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final		to Convert to a nal Application	Proprietary Information
Affidavits/declaration(s)		f Attorney, Revocation of Correspondence Address	Status Letter
Extension of Time Request	Termina	ıl Disclaimer	Other Enclosure(s) (please identify below): return receipt postcard
Express Abandonment Request	Request	for Refund	
Information Disclosure Statement	CD, Nu	mber of CD(s)	
Certified Copy of Priority Document(s)	Remarks		
Response to Missing Parts/ Incomplete Application			
Response to Missing Parts under 37 CFR 1.52 or 1.53			
SIGN	ATURE OF APP	LICANT, ATTORNEY OR A	GENT
Firm or Individual name Shirley Chen, Reg. No	. 44,608, WILSO	ON SONSINI GOODRICH &	k ROSATI
Signature	ms	Elin 24-05	
Date	8-	24-05	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Express Mail Date: August 25, 2005 Express Mail Label No.: EV518897128US

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT Attorney Docket No. 12636-304.201

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Howard SANDS, et al.

Group Art Unit: 1614

Serial Number: 10/698,983

Examiner: Not yet assigned

Filing Date: October 31, 2003

CONFIRMATION NO: 8849

Title: PHARMACEUTICAL FORMULATIONS
TARGETING SPECIFIC REGIONS OF
THE GASTROINTESTINAL TRACT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form(s) PTO/SB/08A. A copy of each listed publication is being submitted, if required, pursuant to 37 C.F.R. §§1.97-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

⊠ becaus		CFR	§1.97	7(b).	This	Information	Disclosure	Statement	should b	e conside	red by th	e Office
			(1)		is othe	filed within a cont						plication
			(2)		being nternat	filed within ional application		f entry of a	national s	tage as se	t forth in {	§1.491 in
	\boxtimes		(3)	It is	being	filed before OR	the mailing	date of the	first Office	Action of	n the merit	ts;
•	. 🗆		(4)		being	filed before ued examinat	•		ffice Action	on after the	e filing of	a request
	spe off clo	cifie ice a ses p	d in 37 ction u	CFF Inder tion o	\$ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	igh this Info 7(b), above, 3, (2) a notion merits, this Info	it is filed be of allowa	efore the n nce under	nailing dat §1.311, or	e of the e (3) an ac	earlier of (ction that of	(1) a final otherwise
			a certii	ficatio		pecified in §	1.97(e) prov	ided concu	rrently her	ewith;		
					80.00	as set forth papers filed t				iclosed, oi	r included	with the
	da	te of is bei	the ear	lier o	f (1) a	igh this Info final office a ment of the	action under	§1.113 or	(2) a notic	e of allow	vance unde	er §1.311,
	A.		a certi	ficatio	on as s	pecified in §	1.97(e); and					•
	В.					as set forth in papers filed t				nclosed, o	or included	d with the
			? §1.97 7 CFR			fication sign	ed by an A	ttorney of I	Record is 1	provided h	nerewith as	s required
Ø	37	CFR	§1.98	(a)(2)	. The	content of th	e Informatio	on Disclosu	re Stateme	nt is as fo	llows:	
		Ì	Copie:			of the reference	nces listed	on the atta	ched Forn	n PTO/SE	3/08A are	enclosed
	\boxtimes]			rm PT	Patent Docum O/SB/08A and AND/OR	re NOT encl		and pater	t publicat	tions) liste	ed on the
	\boxtimes]			oreign	n Patent Doc O/SB/08A at	uments and					ted on the

		AND/OR	
		Copies of pending unpublished U.S. 37 CFR §1.98(a)(2)(iii).	patent applications are enclosed in accordance with
\boxtimes	37 CF.		sure Statement includes non-English patents and/or
•		publication or other information provided DE 1922702 was published in German. Sufficient to convey the scope of its discovery the scope of its discovery. WO 03/040363 was published in Japaneare sufficient to convey the scope of its WO 03/046190 was published in Germa are sufficient to convey the scope of its Should the Examiner believe that a copublications is necessary to understand such translations at the Examiner's requirements of the scope of its Should the Saminer believe that a copublication is necessary to understand such translations at the Examiner's requirements.	the English language abstract and the drawings are closure. 70939 and JP 2003310293 were published in its are sufficient to convey the scope of their ese. The English language abstract and the drawings disclosure. In. The English language abstract and the drawings disclosure. In English language abstract and the drawings disclosure.
		sufficient to convey the scope of its disc	. The English language translation and the drawings
			n corresponding patent application(s), submitted in attached certification under 37 CFR §1.97(e)(1).
\boxtimes	\$0.00 a		by authorized to charge the above-referenced fees of any overpayment associated with this communication 636-304.201).
			Respectfully submitted,
		•	WILSON SONSINI GOODRICH & ROSATI
Dated:		8-24-05	By: Shirley Chen, Reg. No. 44,608

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971 PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Mu.				Con	iplete if Known	
Substitute for	or form 1449	/PTO		Application Number	10/698,983	
INFORM	1ATION I	DISC	LOSURE	Filing Date	10/31/2003	•
STATEN	MENT BY	APP	LICANT	First Named Inventor	Howard Sands	
(Use as	s many sheets	s as ne	cessary)	Art Unit	1614	
				Examiner Name	Not yet assigned	
Sheet	1	of	5	Attorney Docket Number	12636-304.201	

		U.S. PA	ATENT DOC	UMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-2001/0012835 A1	04/14/1997	Fine, et al.	•
		US-2002/0114809 A1	02/21/2001	Rubinfeld, et al.	
		US-2002/0136709 A1	07/31/2001	Zahner	
		US-2003/0013099 A1	03/19/2001	Lasek, et al.	
		US-2003/0039689 A1	04/26/2002	Chen, et al.	
		US-2003/0045497 A1	07/26/2002	Widegren, et al.	
		US-2003/0108588 A1	09/17/2002	Chen, et al.	
		US-2003/0147813 A1	02/07/2002	Lyons	
		US-2003/0165864 A1	01/16/2002	Lasek, et al.	
		US-2003/0171303 A1	06/11/2002	Gallop, et al.	
		US-2003/0229047 A1	06/05/2002	Joshi-Hangal, et al.	
		US-4,690,918	09/01/1987	Beppu, et al.	
		US-5,736,531	12/30/1993	Von Borstel, et al.	
		US-5,856,090	09/09/1994	Epstein	
		US-5,856,094	06/30/1995	Sidransky, et al.	
		US-5,968,914	10/28/1987	Von Borstel, et al.	
		US-6,136,791	12/23/1996	Nyce	
		US-6,255,293 B1	07/24/1998	Kimchi	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known 10/698,983 Application Number Substitute for form 1449/PTO Filing Date 10/31/2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor **Howard Sands** (Use as many sheets as necessary) Art Unit 1614 **Examiner Name** Not yet assigned Sheet of 2 5 Attorney Docket Number 12636-304.201

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
		CS 269077	12/22/1963	Ceskoslovenska akademie ved, (Prag)		
		DE 1922702	05/03/1969	Ceskoslovenska akademie ved, (Prag)	· ·	
		DE 2105468	02/05/1971	Ceskoslovenska akademie ved, (Prag)		
		EP 286958	04/06/1988	Merck Pg		
		JP 05219974	02/13/1992	Mitsui Petrochem Ind Ltd		
		JP 2002223753	01/30/2001	Hitachi		Г
		JP 2002370939	06/12/2001	Taisho Pharmaceutical Co. Ltd.	•	
		JP 2003310293	04/26/2002	Mitsui Chemical Inc.		T
		PCT/US04/22367 International Search Report	07/20/2005	SuperGen, Inc.		T
		WO 93/01202	07/05/1991	Pro-Neuron, Inc.		T
•		WO 94/26761	05/14/1993	Pro-Neuron, Inc.		T
		WO 94/27632	06/01/1993	Nycomed Pharma A/S		T
,		WO 96/11280	10/07/1994	East Carolina University		T
	*	WO 96/36693	05/19/1995	Phytera, Inc.		T
		WO 96/39035	06/06/1995	Case Western Reserve Unniversity		
		WO 96/40165	06/07/1995	Pro-Neuron, Inc.		T
		WO 98/14619	10/03/1996	Incyte Pharmaceuticals, Inc.		
		WO 98/16186	10/16/1996	ICN Pharmaceuticals		T
		WO 98/29108	12/30/1996	Andrew, P. Feinberg		T
		WO 98/54318	05/28/1997	Marie Curie Research Institute		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Considered

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

12636-304.201

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known 10/698,983 Application Number Substitute for form 1449/PTO Filing Date 10/31/2003 INFORMATION DISCLOSURE First Named Inventor . STATEMENT BY APPLICANT **Howard Sands** (Use as many sheets as necessary) Art Unit 1614 **Examiner Name** Not yet assigned

Attorney Docket Number

of

5

3

Sheet

			PATENT DO			_
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
		WO 00/05419	07/24/1998	Yeda Research and	Retevant rigures repress	\top
		1		Development		
				Company Ltd.		
		WO 00/23112	10/19/1998	Methylgene, Inc.		
		WO 00/40269	01/05/1999	Clarence Lee		T
		WO 00/54574	03/18/1999	The University of Chicago		T
		WO 00/62075	04/13/1999	Rutgers, The State University of New Jersey		
		WO 01/21215 A1	09/22/1999	Ortho-McNeil Pharmaceutical, Inc.		
		WO 01/69262 A1	03/15/2000	University of Massachusetts		
		WO 01/79164 A2	03/21/2000	Atherogenics, Inc.		Т
		WO 02/18592 A1	09/01/2000	Bionomics Limited		T
		WO 02/21140 A1	09/08/2000	Metabolic Engineering Laboratories Co., Ltd.		T
		WO 02/051980 A2	12/12/2000	Nucleus Remodeling, Inc.		
		WO 02/057425 A2	01/22/2001	Merck & Co., Inc.		T
		WO 02/069903 A3	03/06/2001	Biocryst Pharmaceuticals, Inc.		
		WO 02/076486 A2	02/05/2001	Innoventus Project AB		Τ
		WO 02/083705 A1	04/13/2001	The Johns Hopkins University School of Medicine		
· · · · · · · · · · · · · · · · · · ·		WO 02/085400 A1	04/24/2001	Supergen, Inc.		
		WO 02/087586 A1	04/26/2001	Control Delivery Systems, Inc.		Ī
		WO 03/006950 A2	07/12/2001	Geron Corporation		1

Signature | Considered |
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Translation is attached.

ter the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMR control number.

				Con	nplete if Known
Substitute for form 1449/PTO		Application Number	10/698,983		
INFORM	MATION	DISC	LOSURE	Filing Date	10/31/2003
STATEMENT BY APPLICANT		First Named Inventor	Howard Sands		
(Use a	(Use as many sheets as necessary)			Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	4	of	5	Attorney Docket Number	12636-304.201

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		WO 03/012112 A1	07/27/2001	Geneinvent BBL AB		Т
	-	WO 03/012085 A1	07/30/2001	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.		
		WO 03/011209 A2	07/31/2001	Yeda Research and Development Co. Ltd.		
		WO 03/026574 A2	09/24/2001	AU, Jessie, LS.	_	
		WO 03/031932 A2	10/05/2001	Case Western Reverse Univresity		
		WO 03/040363 A1	11/08/2001	Japan Science and Technology Corporation		
		WO 03/043631 A2	11/23/2001	F. Hoffman-LA Roche AG		T
		WO 03/045427 A2	11/29/2001	Dandrit Biotech A/S		T
		WO 03/046190 A1	11/30/2001	Medigene Aktiengesellschaft		T
• 11.1		WO 03/065995 A2	02/07/2002	SuperGen, Inc.		T
		WO 03/076593 A2	03/07/2002	The Johns Hopkins University School of Medicine		
		WO 03/076594 A2	03/07/2002	The Johns Hopkins University		
		WO 03/086374 A1	04/05/2002	University of Utah Research Foundation		
		WO 2003/087774 A3	04/12/2002	Gurators of the University of Missouri		
		WO 03/104427 A2	06/05/2002	Case Western Reserve University		
		WO 2004/009023 A2	07/18/2002	University of Utah Research Foundation		Γ

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Considered

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/698,983 Application Number INFORMATION DISCLOSURE 10/31/2003 Filing Date STATEMENT BY APPLICANT First Named Inventor **Howard Sands** (Use as many sheets as necessary) 1614 Art Unit **Examiner Name** Not yet assigned 12636-304.201 Attorney Docket Number Sheet 5 of 5

		NON PATENT LITERATURE DOCUMENTS					
	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		VON HOFF, et al., "5-Azacytidine. A New Anticancer Drug With Effectiveness in Acute Myelogenous Leukemia," <i>Annals of Internal Medicine</i> (1976) 85(2), pages 237-245					
Examiner ignature		Date Considered					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.